Welcome to our dedicated page for Seer SEC filings (Ticker: SEER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Seer, Inc.'s SEC filings document material events, operating results, securityholder rights and governance matters for a Nasdaq-listed life sciences company focused on research-use proteomics. Recent 8-K reports cover results of operations and financial condition, material definitive agreements, modifications to securityholder rights, other events and related exhibits.
The filings disclose Seer's Class A common stock, Preferred Stock Purchase Rights, Tax Benefit Preservation Plan for net operating loss and other tax attributes, amendments to that plan, and the completed conversion of Class B common stock into Class A common stock. They also record board and shareholder matters, leadership appointments, and intellectual-property updates related to the Proteograph Product Suite and particle-based protein enrichment.
Bradley L. Radoff, Michael Torok and affiliates, collectively known as the Radoff-JEC Group, filed proxy materials as part of a contested director election at Seer, Inc. They state they own approximately 7.7% of Seer’s outstanding common stock and are soliciting votes at the 2026 annual meeting using a WHITE universal proxy card.
The group is asking stockholders to support its three director nominees – Howard H. Berman, Ph.D., Luis E. Rinaldini and Joshua S. Horowitz – and to withhold support from incumbent directors Terrance McGuire, Dipchand (Deep) Nishar and Omid Farokhzad, M.D. They also urge voting against ratification of Seer’s Tax Benefit Preservation Plan, which they refer to as an NOL pill. The Radoff-JEC Group argues that Seer should be sold to the highest bidder and that new, independent directors are needed to run a “robust and transparent” review of strategic alternatives aimed at maximizing value for all stockholders.
The Radoff-JEC Group, which reports owning approximately 7.7% of Seer, Inc.’s outstanding common stock, is soliciting votes on a WHITE universal proxy card for three director nominees at Seer’s 2026 annual meeting. The group highlights that proxy advisory firms Glass Lewis and ISS have supported its case for change, with Glass Lewis recommending stockholders vote for nominees Howard H. Berman and Luis E. Rinaldini, withhold support from incumbent directors Terrance McGuire and Dipchand Nishar, and vote against ratification of the NOL pill. The Radoff-JEC Group argues that Seer has experienced prolonged underperformance and operating losses and urges election of its nominees to enhance board independence and oversee a strategic review ahead of the Company’s July 28 annual meeting.
Seer, Inc. reported that a Special Committee of its Board of Directors, composed of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., has thoroughly reviewed and unanimously rejected an unsolicited, non-binding proposal received on July 1, 2026 from Chair and CEO Omid Farokhzad, M.D.
The Proposal sought to acquire all outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two contingent value rights. After consulting independent advisors, the Special Committee determined the Proposal is not in the best interests of stockholders because it undervalues Seer and does not adequately reflect its long-term growth prospects, noting that the contingent value rights were insufficient to capture the potential value of Seer’s technology.
Seer, Inc. director Dipchand Nishar reported an open-market sale of 10,660 shares of Class A Common Stock at a weighted average price of $2.18 per share on July 8, 2026. The transaction was executed under a Rule 10b5-1 trading plan adopted on August 8, 2025 to cover tax obligations upon vesting and settlement of restricted stock units. Following the sale, he directly holds 59,044 shares.
Seer, Inc. received an unsolicited, non-binding proposal from its Chair and CEO, Omid Farokhzad, M.D., to take the company private by acquiring all outstanding Class A shares he does not already own for $2.45 per share in cash plus two contingent value rights (CVRs).
The cash offer represents a 41% premium to Seer’s 30‑day volume weighted average price as of June 30, 2026, and, assuming full CVR payment, a 222% premium. One CVR can pay up to $0.25 per share based on 2031 revenue milestones, and another can pay up to $2.91 per share based on the value of a qualifying sale or strategic transaction within five years of closing.
The board will form a Special Committee of independent directors, with its own legal and financial advisors, to evaluate this proposal and other alternatives. The proposal is fully financed, subject to due diligence, definitive agreements, customary approvals, and a majority-of-the-minority shareholder vote. Seer stated that no stockholder action is required at this time.
Seer, Inc.: a dissident stockholder group led by Bradley L. Radoff and Michael Torok (the “Radoff-JEC Group”), which collectively owns ~7.7% of Seer, filed a definitive proxy and is soliciting votes at the July 28, 2026 annual meeting to replace three directors with Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini. The presentation alleges the incumbent board oversaw a 97.0% share‑price decline since the December 2020 IPO, cumulative reported losses exceeding $465 million, and more than $310 million of cash burned since the IPO. The dissidents say they submitted three fully financed acquisition proposals (up to $2.40 per share plus a CVR) that were rejected without engagement and urge a strategic review, cost cuts, potential repurchases and revocation/ratification of the NOL pill.